Analyst Speak: 

“The Radiopharmaceuticals/Nuclear Medicine Market is growing at significant growth rate over the forecast period 2019-2025 and expected to reach US$ 9,348.6 Mn by 2025, due to rise in prevalence of cancer and other chronic diseases”

Precision Business Insights (PBI) in its report titled “Radiopharmaceuticals/Nuclear Medicine Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period from 2019 to 2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.

The global radiopharmaceuticals/nuclear medicine market projected to reach US$ 9,348.6 Mn by 2025. The market is growing at prominent growth rate over the forecast years owing to increase in the prevalence of chronic diseases such as cancer, cardiovascular, and neurological disorders. For instance, according to WHO 2018 data, approximately 9.6 Mn death occurred due to cancer and approximately 17.9 Mn deaths occurred due to cardiovascular disorders around the world. Moreover, rise in R&D for the development of innovative therapeutics, rise in demand for personalized medicine, and favorable reimbursement policies in developed countries. However, high cost of radiopharmaceuticals/nuclear medicine, severe adverse effects with radiopharmaceuticals, and stringent regulatory guidelines for the product approval are the factors impede the radiopharmaceuticals/nuclear medicine market over the forecast timeframe

Avail Sample Report of the Market @ https://www.precisionbusinessinsights.com/request-sample?product_id=17441 

Radiopharmaceuticals/nuclear medicine market segmented on the basis of product type, application, route of administration, end user, and region.

Diagnostic Segment Expected to Dominate the Radiopharmaceuticals/Nuclear Medicine Market 

Based on product type, the radiopharmaceuticals/nuclear medicine market is segmented into diagnostic radiopharmaceuticals and therapeutic radiopharmaceuticals. Diagnostic radiopharmaceuticals expected to dominate the global radiopharmaceuticals/nuclear medicine market owing to frequent product approvals and wide range of diagnostic applications with SPECT products such as Tc-99m. Moreover, therapeutic radiopharmaceuticals projected to grow at prominent growth rate due to surge in the R&D activities for the development of newer therapeutics for targeted treatment of various types of cancers. For instance, in January 2018, Norgine B.V. launched Lymphoseek (Tc 99m tilmanocept) in Finland and Sweden. Lymphoseek is specifically designed to target, bind, and retain in the sentinel lymph nodes to prevent the cancer 

North America Accounts for Major Revenue Share for Radiopharmaceuticals/Nuclear Medicine Market 

Precision Business Insights (PBI), radiopharmaceuticals/nuclear medicine market report analyses the market in different regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa. Among the all regions, North America accounted for major revenue share in global radiopharmaceuticals/nuclear medicine market and the market is expected to grow at significant growth rate over the forecast years owing to favorable reimbursement policies, increase in the prevalence of cancer and cardiovascular diseases, and presence of huge number of market players in the region. In addition, Asia Pacific radiopharmaceuticals/nuclear medicine market creates lucrative opportunities over the forecast years owing to surge in the health awareness among the population and rise in medical tourism in the Asia Pacific region.

Strategic Alliances and Launch of Newer Tests in Radiopharmaceuticals/Nuclear Medicine Market 

In October 2018, Novartis entered into merger agreement with ndocyte, a US-based biopharmaceutical company to develop the novel radiopharmaceuticals for the treatment of targeted diseases

Key player’s profiles in the report are Advanced Accelerator Applications S.A. (France), Bayer AG (Germany), Bracco Imaging S.p.A (Italy), Cardinal Health, Inc. (U.S.), Eli Lilly and Co. (U.S.), GE Healthcare (U.S.), Jubilant Life Sciences Ltd (India), Lantheus Medical Imaging, Inc. (U.S.), Navidea Biopharmaceutical (U.S.), Nordion, Inc. (Canada), Norgine B.V. (Netherlands), Siemens Healthineers (Germany), and Novartis AG (Switzerland)

For More Information @ https://www.precisionbusinessinsights.com/market-reports/global-radiopharmaceuticals-nuclear-medicine-market/ 

Detailed Segmentation 

By Product Type

Diagnostic Radiopharmaceuticals
SPECT Radiopharmaceuticals
PET Radiopharmaceuticals
Therapeutic Radiopharmaceuticals
Beta Emitters
Alpha emitters
Brachytherapy
Others

By Application

Oncology
Neurological disorders
Cardiovascular diseases
Thyroid
Others

By Route of Administration

Oral
Inhalation
Parenteral

By End User

Hospitals
Clinics
Diagnostic Centers
Research Institutes

Geography 

North America

US
Canada

Europe

Germany
France
UK
Italy
Spain
Russia
Poland
Rest of Europe

Asia-Pacific

Japan
China
India
Australia & New Zealand
ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
South Korea
Rest of Asia-Pacific

Latin America

Brazil
Mexico
Argentina
Rest of Latin America

Middle East and Africa (MEA)

Gulf Cooperation Council (GCC) Countries
Israel
South Africa
Rest of MEA

About Us:
 
Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights.
 
Contact Us:
 
Shreya Paul
Senior Business Development Executive
Email @ [email protected]
Call @ +1-866-598-1553
Precision Business Insights